News Results
There are 77,406 News Results
Aug 14, 2018
NEW YORK, Aug. 14, 2018 /PRNewswire-PRWeb/ -- Women undergoing breast reconstruction after mastectomy have many options. The gold standard of breast reconstruction is natural tissue breast reconstruction, in which a...
Aug 16, 2018
DUBLIN, Aug 16, 2018 /PRNewswire/ -- The "Airway Management Devices - Global Strategic Business Report" report has been added to
Sep 5, 2018
BALTIMORE, Sept. 5, 2018 /PRNewswire/ -- The University of Maryland (UM) BioPark and UM Ventures announced today that ImmuCision BioTherapeutics (ICBT), a UM, Baltimore startup company specializing in immunotherapy, has...
Sep 10, 2018
INDIANAPOLIS, Sept. 10, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz(®) (ixekizumab), Olumiant(® )(baricitinib) and mirikizumab at the 27(th) annual...
Sep 28, 2018
HAMBURG, Germany, Sept. 28, 2018 /PRNewswire/ -- Sysmex Inostics, a subsidiary of Sysmex Corporation and a global leader in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology,...
Oct 5, 2018
BERGEN
Oct 10, 2018
PHILADELPHIA, Oct. 10, 2018 /PRNewswire/ -- Cognizance Biomarkers, LLC, a wholly-owned subsidiary of Evogen, Inc., a leader in proteomic and genomic-based testing for improved diagnosis and treatment of neurological disorders,...
Oct 22, 2018
SHANGHAI, Oct. 22, 2018 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone), a clinical stage biopharmaceutical company headquartered in Shanghai, today announced the US FDA approval of IND for phase II...
Nov 9, 2018
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib...
Nov 13, 2018
IDAHO FALLS, Idaho, Nov. 13, 2018 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company") in conjunction with the University Of Missouri Research Reactor (MURR), is pleased to announce it...